Key result
High-risk proteomic IFG subtype linked to higher incident diabetes and steeper insulin sensitivity decline.
Why the study?
Does plasma proteome-based subtyping predict incident type 2 diabetes and insulin sensitivity decline in individuals with impaired fasting glucose?
Cohort (n=538)
Yes
Does plasma proteome-based subtyping predict incident type 2 diabetes and insulin sensitivity decline in individuals with impaired fasting glucose?
Deep plasma proteomic profiling can stratify individuals with impaired fasting glucose into distinct risk categories for future type 2 diabetes, potentially enabling more targeted prevention strategies.
AIMS: Prediabetes is biologically heterogeneous, but molecular subtypes linked to diabetes progression remain poorly defined. We aimed to identify plasma proteome-based subtypes of impaired fasting glucose (IFG), characterise their molecular features and assess their association with future diabetes risk. MATERIALS AND METHODS: We quantified 2584 plasma proteins using liquid chromatography-mass spectrometry in 538 IFG participants from a prospective discovery cohort (Nutrition and Health of Aging Population in China, NHAPC). Proteomic subtypes were defined by consensus clustering, linked to longitudinal changes in insulin sensitivity and incident type 2 diabetes mellitus (T2DM), which were further validated in an independent Shanghai Brain Aging Study (SBAS) cohort. RESULTS: Two reproducible IFG molecular subtypes based on plasma proteomics were identified. The high-risk subtype showed higher incident diabetes and a greater 6-year decline in insulin sensitivity and was characterised by enrichment of glycolysis/gluconeogenesis, insulin signalling and neutrophil degranulation, together with a dyslipidemic lipidomic profile indicating co-dysregulation of glucose and lipid homeostasis. The low-risk subtype demonstrated a higher complement cascade and high-density lipoprotein particle remodelling signature. In the high-risk subtype, key proteins and lipids showed stronger associations with longitudinal declines in insulin sensitivity, including PPBP, PGK1 and ALDOA, as well as PE-P 18:0/20:3 and PE-P 18:1/20:3. CONCLUSIONS: Proteome-based molecular subtyping stratifies IFG individuals with similar fasting glucose levels but distinct biology and future diabetes risk, supporting earlier and more targeted prevention.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) conducted a cohort in Impaired fasting glucose (IFG) / Prediabetes (n=538). High-risk proteomic subtype vs. Low-risk proteomic subtype was evaluated on Incident type 2 diabetes mellitus and longitudinal changes in insulin sensitivity. A high-risk plasma proteomic subtype of impaired fasting glucose was associated with higher incident diabetes and a greater 6-year decline in insulin sensitivity compared to a low-risk subtype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: